4//SEC Filing
Binder-Scholl Gwendolyn Knowlton 4
Accession 0001104659-18-002676
CIK 0001621227other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 5:20 PM ET
Size
8.6 KB
Accession
0001104659-18-002676
Insider Transaction Report
Form 4
Binder-Scholl Gwendolyn Knowlton
EVP, Adaptimmune LLC
Transactions
- Award
Option to purchase Ordinary Shares
2018-01-12+96,036→ 96,036 totalExercise: $0.00→ Ordinary Shares (96,036 underlying) - Award
Option to purchase Ordinary Shares
2018-01-12+429,984→ 429,984 totalExercise: $1.30Exp: 2028-01-12→ Ordinary Shares (429,984 underlying)
Footnotes (5)
- [F1]The exercise price was converted from GBP0.96 based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F2]Exercisable as to 107,496 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in monthly installments of 8,958 Ordinary Shares on the twelfth of each month from February 12, 2019 through January 12, 2022.
- [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.3542 - GBP1.00. The actual exercise price will be the pounds sterling amount.
- [F4]Exercisable as to 24,009 Ordinary Shares on January 12, 2019 and will be exercisable as to the remainder in annual installments of 24,009 Ordinary Shares on the twelfth of each January from January 12, 2020 through January 12, 2022.
- [F5]The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001662116
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 5:20 PM ET
- Size
- 8.6 KB